Therefore, one immunotherapeutic approach has been to target the PD-1/PD-L1 axis with inhibitory antibodies to block counter-regulatory signaling in T cells and promote anti-tumor immune responses, which has been highly successful for a subset of patients in various tumor entities, such as lung cancer. Here, PDCD1 is linked to neoplasm.